A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 08 Oct 2017 Results presented at the IDWeek 2017
- 27 Sep 2016 Status changed from recruiting to completed.
- 08 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.